Humanized Mouse Model Market Outlook 2023 to 2033

The global humanized mouse model market size is projected to be worth US$ 101.5 million in 2023. The humanized mouse model market forecasts growth from 2023 to 2033 of 5.8% CAGR to reach US$ 178.3 million.

One of the main drivers of increased research activities in humanized mouse models is the rising demand from the healthcare sector for more thorough screening of novel drug candidates discovered to treat various chronic diseases such as cardiovascular conditions, diabetes, and cancers. From 2017 to 2022, the global humanized mouse and rat model market experienced a CAGR of 5.3%.

Key Market Highlights

  • Using genetically engineered mice in experimental medical research has significantly advanced the understanding of illness and human health.
  • With the development of gene targeting, transgenics, and recent advancements in gene-editing techniques, the manipulation of the mouse genome has improved.
  • More complex models can be made, owing to improvements in genetic engineering techniques, which may increase the usefulness of these models in the research and development of new drugs.
  • As a trustworthy tool for preclinical research, mouse models' utility in predicting gene function is constrained by this divergence.
  • Mice and humans share many genetic traits, although it is also recognized that even very slight sequence differences can have a functional impact on the specific gene functions of each species.
Attributes Details
Humanized Mouse Model Market Value for 2023 US$ 101.5 million
Humanized Mouse Model Market Value for 2033 US$ 178.3 million
Humanized Mouse Model Market CAGR from 2023 to 2033 5.8%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

A Deep Dive From 2018 to 2022 and a Vision From 2023 to 2033 For Humanized Mouse Model Market

The humanized mouse model demand increased steadily between 2017 and 2022, accelerated by increased research into infectious illnesses, cancer, and immunology. These models were frequently utilized by academic institutions and pharmaceutical corporations for preclinical research, creating a stable humanized mouse model market.

Historical CAGR 5.3%
Forecast CAGR 5.8%

The humanized mouse and rat model market is expected to strengthen significantly between 2023 and 2033. The introduction of customized medicine, increased investment in drug research, and an increasing focus on precision medicines are just a few of the factors that have contributed to this surge. The adoption is fueled by the need for trustworthy preclinical models replicating human physiology.

The humanized mice model market is anticipated to have significant expansion, which reflects the dynamic environment of biomedical research and medication development. Several genes have been discovered in humans but have not been discovered in their orthologous mouse counterparts.

These genetically humanized mice can offer more trustworthy in vivo information regarding human gene function in healthy physiology and disease. As a result, creating genetically modified mice that express an orthologous human gene is becoming increasingly popular.

DRIVERS

  • An increase in the need for individualized medication.
  • Government and corporate sector initiatives and ongoing support for cancer research.
  • Expanding research and development in the biotechnology and pharmaceutical industries.

RESTRAINTS

  • Custom humanized models are expensive.
  • Legislation and rules governing the ethical use of animal models in research.

OPPORTUNITY

  • Escalating the need for PDX models that have been given human characteristics.
  • The development of CRISPR as a potent tool for biomedical research.
  • Growing demand for models using humanized rats.

CHALLENGES

  • Other options for using animals in testing.
  • Using humanized mouse models has some drawbacks.

Personalized Medicine Acts as A Catalyst for Market Growth for Humanized Mouse Model

Individual biomarkers are used to customize therapies in precision medicine, also known as personalized medicine. Researchers used mice to generate a PDX model for cancer by injecting immune-compromised mice with patient tumor components. Every mouse undergoes a different course of treatment, shaping patients' distinctive tumor-reduction plans.

The demand for individualized medication is set to rise with the adoption of humanized mouse models. Acute myeloid leukemia (AML) and bladder, breast, lung, pancreatic, and ovarian malignancies are just a handful of the illnesses for which Jackson Laboratory has developed more than 450 different PDX oncology mice models.

As a result of advancements in scientific research, associated tools, and technologies, customized medicine has advanced more quickly. These factors are anticipated to fuel humanized mouse model market expansion during the upcoming years.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Humanized Mouse Models are a Key Asset in Pharmaceutical Research for Safer Medications

Humanized mouse models play an integral part in discovering new drugs by providing a crucial link between laboratory research and clinical trials. These models closely resemble how people react to medications because they have immune systems and genetic makeup similar to humans. This allows researchers to evaluate the safety and efficacy of new treatments during the preclinical stages with more accuracy.

This accuracy lowers the possibility of negative outcomes in subsequent clinical studies, saving time and dollars for pharmaceutical companies. The humanized mouse model market stands to gain greatly due to the continued need for better preclinical models to advance drug development pipelines. These models are crucial in the ongoing search for safer and more potent medications.

Competitive Alternatives Stifles the Humanized Mice Model Market Advancement

Researchers are searching for alternatives to conventional models for human study due to increasing humanized mouse model demand from animal rights organizations to discontinue using animals for experimentation. The use of animals for testing has drawbacks, such as the demand for specialized personnel, protracted protocols, and expensive expenses. The study of diabetes uses various methods and non-traditional species, such as rapid computer simulations, artificial blood vessel testing systems, and cell culture techniques for medication investigation.

In vitro testing techniques, online patient drug registries, simulating virtual drug trials, non-invasive imaging techniques including magnetic resonance imaging (MRI) and computed tomography (CT) scans, micro-dosing, and other options are some newer possibilities.

The development of these techniques can affect how humanized mouse models are used as researchers attempt to reduce the price of drug testing. Non-animal-tested products may rise due to marketing that positions them as environmentally beneficial. These factors are anticipated to restrain the humanized mouse model market expansion throughout the forecasted period.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Comparative View of Adjacent Humanized Mice Model Market

The rat model market and the animal model market have both been studied by Future Market Insights (FMI). The data depict the projected growth of the humanized mice model market from 2023 to 2033 concerning other markets. It showcases the potential for revenue in the additional markets shown below.

Due to rising demand for drug discovery, immunology research, and personalized medicine, the humanized mouse model market is forecast to expand. The humanized mice model market is expanding due to developments in genetic engineering and the demand for more precise preclinical testing. Leading biotechnology and pharmaceutical companies are anticipated to invest in this industry, encouraging innovation and expanding the rat and mouse model market.

Humanized Mouse Model Market

Attributes Humanized Mouse Model Market
Value-based CAGR (2023 to 2033) 5.8%
Projected Market Value (2033) US$ 178.3 million
Market Trends
  • Humanized mouse models are in higher demand as antibodies and vaccines progress.
  • Increased immuno-oncology research demand is propelling the adoption of humanized mouse models.
Growth Factors
  • The demand for patient-specific humanized mouse models is being driven by personalized medicine.
  • Collaborations between academics and industry accelerate market developments.

Rat Model Market

Attributes Rat Model Market
Value-based CAGR (2023 to 2033) 7.8%
Projected Market Value (2033) US$ 2.78 billion
Market Trends
  • Targeted investigations increasingly use genetically altered rat models.
  • Market expansion is fueled by an increase in the usage of rat models in oncology research.
Growth Factors
  • The growing demand for rat models in medication development and disease research encourages market expansion.

Animal Model Market

Attributes Animal Model Market
Value-based CAGR (2023 to 2033) 8.6%
Projected Market Value (2033) US$ 5.20 billion
Market Trends
  • Mice that have been genetically altered are still a common choice in the market for cancer research.
  • Ethical issues and new approaches are contesting traditional uses of animal models.
Growth Factors
  • The increased emphasis on neurodegenerative illnesses propels the demand for primate models.
  • The market is shifting toward larger animals, such as pigs, for translational research.

Category-wise Outlook

Genetic Humanized Mouse Models Segment Takes Center Stage

It is anticipated that the genetic humanized mouse models segment is going to dominate the market. This dominance is primarily related to the extensive use of genetically humanized mouse models in various experimental investigations, notably when evaluating the efficacy and safety of substances. The growing use of these mouse models to study medication metabolism and disposition boosts the humanized mouse model market revenue growth.

Leading Segment Segment Share
Genetic Humanized Mice Model 53.3%

The significance of the genetically humanized mouse model segment is attributed to its critical contribution to accelerating drug discovery and development. Genetic humanized mouse models continue to be actively utilized by pharmaceutical and biotechnology businesses and research organizations, solidifying their position as the industry's significant source of revenue for experimental analysis and drug development.

Oncology's Dominance in the Humanized Mouse Model Industry

Leading the humanized mouse model market expansion is the oncology section, which takes the lead. To understand the biology of cancer, create new treatments, and assess the effectiveness of medications, oncology research mainly relies on humanized mouse models. These models enable more precise and trustworthy preclinical research by simulating the human tumor microenvironment.

Leading Segment Segment Share
Oncology 33.2%

Due to a pressing demand for cutting-edge cancer research and treatment development, the oncology section takes the lead. The demand for humanized mouse models in this research is anticipated to be strong as long as cancer remains a problem for the world's health, promoting advancement and innovation in cancer therapies.

Academic & Research Institutions Segment Spur Humanized Mouse Model Demand

Academic and Research Institutions are the main humanized mouse model demand generators. These organizations are at the bleeding edge of cutting-edge scientific research. They are actively involved in the investigation of numerous diseases, the creation of new medications, and the testing of new therapeutics. The evaluation of innovative treatments and the comprehension of disease mechanisms are made possible using humanized mouse models in preclinical investigations by academic and research institutes.

Leading Segment Segment Share
Academic & Research Institutes 43.9%

Companies in the pharmaceutical and biotechnology industries and contract research organizations considerably contribute to the rat and mouse model market expansion. These organizations use humanized mouse models to speed up drug discovery and development, resulting in faster market entry of safer and more potent pharmaceuticals. The humanized mouse model market’s variety of end-user categories underscores the crucial role that humanized mouse models have played in improving both therapeutic innovation and medical research.

Region-wise Analysis

Promising Growth Prospects of North America's Humanized Mouse Model Market

The humanized mouse model market in North America is anticipated to expand significantly. The demand for customized medicine contributes to the trend, and medication development requires using humanized mouse models for preclinical research. Improvements in genetic engineering and genome editing methods have facilitated the creation of humanized mice models that are more precise and pertinent.

Attributes Details
North America Market Share 41.4%
United States Market Share 32.6%

In North America, pharmaceutical firms and academic institutions increasingly use these models to examine human diseases and evaluate potential treatments. The region's strong healthcare system and significant financial commitments to biomedical research play a role in the rat and mouse model market in North America's promising future.

Gene Editing and Precision Medicine Fuel Market Growth in Europe

Due to its critical contribution to advancing biomedical research and drug discovery, the European rat and mouse model market has a positive outlook. The adoption of humanized mouse models is being boosted by this region's dedication to cutting-edge research and healthcare innovation, allowing for more precise disease modeling and preclinical testing. Developments in gene editing technologies have significantly enhanced the accuracy and applicability of these models.

Attributes Details
Europe Market Share 33.4%
Germany Market Share 7.9%
United Kingdom Market CAGR 5.9%

Humanized mouse models are used more frequently by European pharmaceutical corporations and academic institutions to study diseases, assess prospective treatments, and create customized medicine methods. The European humanized mouse model market benefits from a strong healthcare infrastructure and significant investments in the life sciences industry, strengthening its position as a center for creating humanized mouse models.

Asia Pacific's Scientific Innovation is a Promising Path for Humanized Mouse Models

The Asia Pacific humanized mouse model market is expected to grow rapidly in the future years. The region's booming pharmaceutical and biotechnology companies and a growing emphasis on precision medicine are propelling the use of humanized mouse models for preclinical research. Advances in genetic engineering and genome editing techniques have created more sophisticated and relevant models, increasing their utility in disease modeling and medication testing.

Attributes Details
India Market CAGR 5.8%
China Market CAGR 7.0%
Japan Market Share 4.1%

In Asia Pacific, academic institutions, research organizations, and pharmaceutical corporations progressively incorporate these models into their research workflows. The Asia Pacific is emerging as a leading global humanized mouse model market player. It has substantial potential for innovation and scientific development due to a growing healthcare infrastructure and increased investments in life sciences.

Competitive Analysis

Due to the rising need for preclinical research tools in immunology and drug development, the humanized mouse model industry has a dynamic and varied competitive environment. These businesses use genetic modification methods like CRISPR/Cas9 to create customized mouse models and provide a wide range of humanized mouse models and related services.

Collaborations with pharmaceutical and biotechnology companies for illness modeling and medication testing accelerate competition. Emerging humanized mouse model manufacturers break into the industry, encouraging innovation and healthy competition.

Recent Paradigm Shifts

Company Taconic Biosciences
Details The huNOG-EXL EA humanized immune system (HIS) mouse was introduced in January 2022 by Taconic Biosciences, a leader in providing drug research animal model solutions. Taconic's widely utilized HIS portfolio is widened with this offering. The study window in which a myeloid-lineage HIS mouse model can be successfully used is greatly extended by huNOG-EXL EA.
Company genOway
Details Axenis, a firm committed to the creation of immunocompromised models for the validation of novel and innovative therapies, was acquired by genOway, a biotechnology company focused on the design and development of preclinical models, in September 2021.
Company The Jackson Laboratory
Details The Jackson Laboratory (JAX), a nonprofit biomedical research organization, announced in October 2021 that it has acquired the Research Models & Services (RMS) division of Charles River Laboratories Japan as a wholly owned subsidiary. The Jackson Laboratory Japan, a company based in Japan, has about 250 workers, three production facilities in Atsugi, Hino, and Tsukuba, as well as an administrative office in Yokohama.

Prominent Humanized Mouse Model Manufacturers

  • Ingenious Targeting Laboratory
  • Axenis S.A.S
  • Trans Genic Inc.
  • Horizon Discovery Group PLC
  • HuMurine Technologies
  • Champions Oncology Inc.
  • Genoway S.A.
  • Crown Bioscience Inc.
  • Taconic Biosciences Inc.
  • The Jackson Laboratory
  • Vitalstar Biotechnology Co. Ltd.

Key Segments

By Model Type:

  • Genetic
  • Cell-based
    • CD34
    • PBMC
    • BLT

By Application:

  • Oncology
  • Immunology and Infectious Diseases
  • Neuroscience
  • Toxicology
  • Hematopoiesis
  • Other Applications

By End User:

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academic & Research Institutions

By Region:

  • North America
  • Europe
  • Asia Pacific
  • The Middle East & Africa
  • Latin America

Frequently Asked Questions

What is the Current Humanized Mouse Model Market Valuation?

The humanized mouse model market to secure a valuation of US$ 101.5 million in 2023.

How Big Can the Humanized Mouse Model Market Be by 2033?

The humanized mouse model market is estimated to reach US$ 178.3 million by 2033.

What is the Growth Potential of the Market?

Through 2033, the market is anticipated to expand at a 5.8% CAGR.

What Was the Historical Outlook of the Market?

From 2017 to 2022, the market recorded a 5.3% HCAGR.

Which Model Type Segment to Dominate in the Market?

The genetic humanized mice model sector is set to achieve a market share of 53.3%.

Which End-user Segment to Lead the Humanized Mouse Model Market?

A 43.9% mice model market share is expected for the academic & research institutes sector.

What is the Growth Outlook of China Market?

The China humanized mouse and rat model market to exhibit a CAGR of 7.0% through 2033.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Producers

            3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Model Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Model Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Model Type, 2023 to 2033

        5.3.1. Genetic

        5.3.2. Cell-based

            5.3.2.1. CD34

            5.3.2.2. PBMC

            5.3.2.3. BLT

    5.4. Y-o-Y Growth Trend Analysis By Model Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Model Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Application, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Application, 2023 to 2033

        6.3.1. Oncology

        6.3.2. Immunology and Infectious Diseases

        6.3.3. Neuroscience

        6.3.4. Toxicology

        6.3.5. Hematopoiesis

        6.3.6. Others

    6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End User, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End User, 2023 to 2033

        7.3.1. Pharmaceutical & Biotechnology Companies

        7.3.2. Contract Research Organizations

        7.3.3. Academic & Research Institutions

    7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. U.S.

            9.2.1.2. Canada

        9.2.2. By Model Type

        9.2.3. By Application

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Model Type

        9.3.3. By Application

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Model Type

        10.2.3. By Application

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Model Type

        10.3.3. By Application

        10.3.4. By End User

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. U.K.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Model Type

        11.2.3. By Application

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Model Type

        11.3.3. By Application

        11.3.4. By End User

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Model Type

        12.2.3. By Application

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Model Type

        12.3.3. By Application

        12.3.4. By End User

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Model Type

        13.2.3. By Application

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Model Type

        13.3.3. By Application

        13.3.4. By End User

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Model Type

        14.2.3. By Application

        14.2.4. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Model Type

        14.3.3. By Application

        14.3.4. By End User

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Model Type

        15.2.3. By Application

        15.2.4. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Model Type

        15.3.3. By Application

        15.3.4. By End User

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. U.S.

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Model Type

            16.1.2.2. By Application

            16.1.2.3. By End User

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Model Type

            16.2.2.2. By Application

            16.2.2.3. By End User

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Model Type

            16.3.2.2. By Application

            16.3.2.3. By End User

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Model Type

            16.4.2.2. By Application

            16.4.2.3. By End User

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Model Type

            16.5.2.2. By Application

            16.5.2.3. By End User

    16.6. U.K.

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Model Type

            16.6.2.2. By Application

            16.6.2.3. By End User

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Model Type

            16.7.2.2. By Application

            16.7.2.3. By End User

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Model Type

            16.8.2.2. By Application

            16.8.2.3. By End User

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Model Type

            16.9.2.2. By Application

            16.9.2.3. By End User

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Model Type

            16.10.2.2. By Application

            16.10.2.3. By End User

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Model Type

            16.11.2.2. By Application

            16.11.2.3. By End User

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Model Type

            16.12.2.2. By Application

            16.12.2.3. By End User

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Model Type

            16.13.2.2. By Application

            16.13.2.3. By End User

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Model Type

            16.14.2.2. By Application

            16.14.2.3. By End User

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Model Type

            16.15.2.2. By Application

            16.15.2.3. By End User

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Model Type

            16.16.2.2. By Application

            16.16.2.3. By End User

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Model Type

            16.17.2.2. By Application

            16.17.2.3. By End User

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Model Type

            16.18.2.2. By Application

            16.18.2.3. By End User

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Model Type

            16.19.2.2. By Application

            16.19.2.3. By End User

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Model Type

            16.20.2.2. By Application

            16.20.2.3. By End User

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Model Type

            16.21.2.2. By Application

            16.21.2.3. By End User

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2022

            16.22.2.1. By Model Type

            16.22.2.2. By Application

            16.22.2.3. By End User

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2022

            16.23.2.1. By Model Type

            16.23.2.2. By Application

            16.23.2.3. By End User

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Model Type

        17.3.3. By Application

        17.3.4. By End User

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Ingenious Targeting Laboratory

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

                18.1.1.5.2. Product Strategy

                18.1.1.5.3. Channel Strategy

        18.1.2. Axenis S.A.S

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

                18.1.2.5.2. Product Strategy

                18.1.2.5.3. Channel Strategy

        18.1.3. Trans Genic Inc.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

                18.1.3.5.2. Product Strategy

                18.1.3.5.3. Channel Strategy

        18.1.4. Horizon Discovery Group PLC

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

                18.1.4.5.2. Product Strategy

                18.1.4.5.3. Channel Strategy

        18.1.5. HuMurine Technologies

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

                18.1.5.5.2. Product Strategy

                18.1.5.5.3. Channel Strategy

        18.1.6. Champions Oncology Inc.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

                18.1.6.5.2. Product Strategy

                18.1.6.5.3. Channel Strategy

        18.1.7. Genoway S.A.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

                18.1.7.5.2. Product Strategy

                18.1.7.5.3. Channel Strategy

        18.1.8. Crown Bioscience Inc.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

                18.1.8.5.2. Product Strategy

                18.1.8.5.3. Channel Strategy

        18.1.9. Taconic Biosciences Inc.

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

                18.1.9.5.2. Product Strategy

                18.1.9.5.3. Channel Strategy

        18.1.10. The Jackson Laboratory

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

                18.1.10.5.2. Product Strategy

                18.1.10.5.3. Channel Strategy

        18.1.11. Vitalstar Biotechnology Co. Ltd.

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

                18.1.11.5.2. Product Strategy

                18.1.11.5.3. Channel Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Infectious Disease Diagnostics Market

January 2016

REP-GB-1208

June 2024

250 pages

Healthcare

Cancer Diagnostics Market

March 2021

REP-GB-1090

August 2023

315 pages

Healthcare

Anatomic Pathology Market

August 2020

REP-GB-12370

July 2022

290 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Humanized Mouse Model Market